查看文章

Whereas, B-cell depletion has proven very efficient at controlling disease activity in several auto-immune diseases, including MS, long-term or rare side effects of the treatment remain unknown. Adverse events related to B-cell depletion are notably an increase in the risk of shingles, herpesvirus infection or hypogammaglobulinemia [1]. Palmo-plantar pustulosis (PPP) and oral lichen planus (OLP) are T-cellmediated cutaneous diseases that have been associated with rituximab. We report the occurrence of these cutaneous diseases in two multiple sclerosis patients treated with ocrelizumab.